Anti-angiogenic Therapy on Hepatocellular Carcinoma Development and Progression

Journal of Surgical Research

Volumn 158, Issue 1, 2010, Pages 69-76

  Ishii, Yuji ^a   Sakamoto, Taro ^a   Ito, Rysuke ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

angiogenesis; anti angiogenic therapy; chemoprevention; hepatocellular carcinoma; IL 8; tumor dormancy

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENESIS INHIBITOR; DIETHYLNITROSAMINE; FR 118487; INTERLEUKIN 8; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER PREVENTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER NODULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY;

ALPHA-FETOPROTEINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; DIETHYLNITROSAMINE; DISEASE PROGRESSION; INTERLEUKIN-8; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; RATS, INBRED F344; SPIRO COMPOUNDS;

EID: 71649103286     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.09.015     Document Type: Article

References (25)

1. Li C.Y., Shan S., Huang Q., et al. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2000) 143
2. Masaka A. Sequential immunohistochemical study of early hepatocellular carcinoma in rat liver during carcinogenesis induced by diethylnitrosamine. St Mariana Med J (Japanese) 20 (1992) 472
3. Otsuka T., Okawa T., Shibata T., et al. A new potent angiogenesis inhibitor, FR-118487. J Microbiol Biotechnol 1 (1991) 163
4. Terano H., Shibata T., and Otsuka T. Angiogenesis inhibitors of microbial origin. Drug Future 18 (1993) 239
5. Skinner S.A., Tutton P.J.M., and O'Brien P.E. Microvascular architecture of experimental colon tumors in the rat. Cancer Res 50 (1990) 2411
6. Tsuda H., Masui T., and Inoue T. Three-dimensional observation of vasculature and blood supply during hepatocarcinogenesis in rats. Saishinigaku (Japanese) 41 (1986) 67
7. Guesdon J.L., Ternynck T., and Avrames S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 27 (1979) 1131
8. Wamke R., and Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: A biotin-avidin-horseradish peroxidase method. J Histochem Cytochem 28 (1980) 771
9. Yoshiji H., Kuriyama S., Ways D.K., et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59 (1999) 4413
10. Kimura H., Nakajima T., Karawa K., et al. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver 18 (1998) 14
11. Moriguchi M., Nakajima T., Kimura H., et al. The copper chelator trientine has an anti-angiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 102 (2002) 445
12. Thomas M.B., Chadha R., Glover K., et al. Phase 2 study of erlotinib with unresectable hepatocellular carcinoma. Cancer 110 (2007) 1059
13. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285 (1971) 1182
14. Hui C.S., and Zaho Y.T. Angiogenesis in hepatocellular carcinoma: The retrospectives and perspectives. J cancer Res Clin Oncol 130 (2004) 307
15. Zhong L.Z., Zhi S.L., and Quan S. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J Gastroenterol 11 (2005) 216
16. Schwartz M., Roayaie S., and Knostadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4 (2007) 424
17. Glaser B.M. Extracellular modulating factors and the control of intraocular neovascularization: An overview. Arch Opthamol 106 (1988) 603
18. Lisa M.C., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860
19. Nakamura S., Muro H., Suzuki S., et al. Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma. Hepatology 26 (1997) 407
20. Frachon S., Gouysse G., Dumortier J., et al. Endothelial cell marker expression in dysplastic lesions of the liver: An immunohistochemical study. J Hepatol 34 (2001) 850
21. Newman P., Berndt M., Gorski J., et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247 (1990) 1219
22. Arenberg D.A., Kunkel S.L., Polverini P.J., et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97 (1996) 2792
23. Kubo F., Ueno S., Hiwatashi K., et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol 12 (2005) 800
24. Ishii Y., Nakasato Y., Yanagisawa S., et al. Dose anti-angiogenic treatment make any contribution in cases of primary hepatocellular carcinoma? With special reference to chemoprevention, tumor dormancy and tumor shrinkage. Bioterapy (Japanese) 16 (2002) 396
25. Ueoka M. Inhibitory effects of the angiogenesis inhibitor FR-118487 on liver metastasis in a rabbit colon cancer model by continuous intraarterial infusion. Jpn J Gastroenterol Surg (Japanese) 32 (1999) 983